Nuclear Rac1 regulates the bFGF-induced neurite outgrowth in PC12 cells

Rac1 plays a key role in neurite outgrowth via reorganization of the actin cytoskeleton. The molecular mechanisms underlying Rac1-mediated actin dynamics in the cytosol and plasma membrane have been intensively studied, but the nuclear function of Rac1 in neurite outgrowth has not yet been addressed. Using subcellular fractionation and immunocytochemistry, we sought to explore the role of nuclear Rac1 in neurite outgrowth. bFGF, a strong agonist for neurite outgrowth in PC12 cells, stimulated the nuclear accumulation of an active form of Rac1. Rac1-PBR (Q) mutant, in which six basic residues in the polybasic region at the C-terminus were replaced by glutamine, didn’t accumulate in the nucleus. In comparison with control cells, cells expressing this mutant form of Rac1 displayed a marked defect in extending neurites that was concomitant with reduced expression of MAP2 and MEK-1. These results suggest that Rac1 translocation to the nucleus functionally correlates with bFGF-induced neurite outgrowth. [BMB Reports 2013; 46(12): 617-622]     

Therapeutic angiogenesis for revascularization in peripheral artery disease

Therapeutic angiogenesis for peripheral artery disease (PAD), achieved by gene and cell therapy, has recently raised a great deal of hope for patients who cannot undergo standard revascularizing treatment. Although pre-clinical studies gave very promising data, still clinical trials of gene therapy have not provided satisfactory results. On the other hand, cell therapy approach, despite several limitations, demonstrated more beneficial effects but initial clinical studies must be constantly validated by larger randomized, multi-center, double-blinded, placebo-controlled trials. This review focuses on previous and recent gene and cell therapy studies for limb ischemia, including both experimental and clinical research, and summarizes some important papers published in this field. Moreover, it provides a short comment on combined gene and cell therapy approach on the example of heme oxygenase-1 overexpressing cells with therapeutic properties.     

MMP - 9、VEGF、bFGF 在非何杰金淋巴瘤的表达及临床意义

目的：探讨MMP-9、VEGF、bFGF在非何杰金淋巴瘤（NHL）中的表达及意义。方法：免疫组化法。结果MMP-9、VEGF、bFGF在NHL中表达率分别为43．66％、33．80％、25．35％,均高于正常淋巴结组织中的表达,差异均有显著性（Pm=0．0023,Pv=0．001,Pb=0．0049）。组5年生存率明显低于MMP-9（-）组（P=0．008）。VEGF在T细胞型中表达率高于B细胞型（P=0．019）,VEGF阳性组治疗缓解率低（P=0．045）。巨块型NHL中bFGF表达率较高（P=0．028）,bFGF（＋）组5年生存率明显低于bFGF（-）组（P=0．041）。MMP-9、VEGF、bFGF之间无协同表达。结论：MMP-9、VEGF、bFGF在NHL中的表达高于正常淋巴组织,可能与淋巴组织恶变有关。MMP-9、bFGF均与生存期呈负相关,是NHL预后差的指标,联合检测更有助于判断预后。VEGF阳性组治疗效果差,提示VEGF阳性NHL患者加用VEGF靶向治疗可能会提高疗效。     

Soluble production and function of vascular endothelial growth factor/basic fibroblast growth factor complex peptide

Vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) are important proangiogenic factors in tumor procession. The autocrine and paracrine bFGF and the VEGF in tumor tissue can promote tumor angiogenesis, tumor growth, and metastasis. A VEGF/bFGF Complex Peptide (VBP3) was designed on the basis of epitope peptides from both VEGF and bFGF to elicit in vivo production of anti‐bFGF and anti‐VEGF antibodies. In this study, we reported on the production of recombinant VBP3 using high cell density fermentation. Fed‐batch fermentation for recombinant VBP3 production was conducted, and the production procedure was optimized in a 10‐L fermentor. The fraction of soluble VBP3 protein obtained reached 78% of total recombinant protein output under fed‐batch fermentation. Purified recombinant VBP3 could inhibit tumor cell proliferation in vitro and stimulate C57BL/6 mice to produce high titer anti‐VEGF and anti‐bFGF antibodies in vivo. A melanoma‐grafted mouse model and an immunohistochemistry assay showed that tumor growth and tumor angiogenesis were significantly inhibited in VBP3‐vaccinated mice. These results demonstrated that soluble recombinant VBP3 could be produced by large‐scale fermentation, and the product, with good immunogenicity, elicited production of high‐titer anti‐bFGF and anti‐VEGF antibodies, which could be used as a therapeutic tumor vaccine to inhibit tumor angiogenesis and tumor growth. © 2014 American Institute of Chemical Engineers Biotechnol. Prog., 31:194–203, 2015     

Differential expression of cell surface proteins in human bone marrow mesenchymal stem cells cultured with or without basic fibroblast growth factor containing medium

Mesenchymal stem cells (MSCs) are multipotent cells, which have the capability to differentiate into various mesenchymal tissues such as bone, cartilage, fat, tendon, muscle, and marrow stroma. However, they lose the capability of multi‐lineage differentiation after several passages. It is known that basic fibroblast growth factor (bFGF) increases growth rate, differentiation potential, and morphological changes of MSCs in vitro. In this report, we have used 2‐DE coupled to MS to identify differentially expressed proteins at the cell membrane level in MSCs growing in bFGF containing medium. The cell surface proteins isolated by the biotin–avidin affinity column were separated by 2‐DE in triplicate experiments. A total of 15 differentially expressed proteins were identified by quadrupole‐time of flight tandem MS. Nine of the proteins were upregulated and six proteins were downregulated in the MSCs cultured with bFGF containing medium. The expression level of three actin‐related proteins, F‐actin‐capping protein subunit alpha‐1, actin‐related protein 2/3 complex subunit 2, and myosin regulatory light chain 2, was confirmed by Western blot analysis. The results indicate that the expression levels of F‐actin‐capping protein subunit alpha‐1, actin‐related protein 2/3 complex subunit 2, and myosin regulatory light chain 2 are important in bFGF‐induced morphological change of MSCs.     

bFGF活性稳定性的研究

目的：研究bEGF的生物活性稳定性。方法：通过在不同稳定剂中,改变bEGF与肝素钠结合的比例,经MTT法检测bEGF生物活性。结果：以甘露酵、甘油和人血白蛋白作物稳定剂时,bEGF与肝素钠的最佳结合比例为3：1,以海藻糖作稳定剂时,bEGF与肝素钠的最佳结合比例为1：1,以右旋糖苷作稳定剂时,bEGF与肝素钠的最佳结合比例为2：1。以右旋糖苷作稳定剂最好,在甘露酵、甘油和人血白蛋白稳定剂较好,以海藻糖作稳定剂稍差。结论：配方中有肝素钠存在可明显提高bEGF的生物活性。     

三七皂苷R1对大鼠缺血心肌VEGF、bFGF的影响

目的:探讨三七皂苷R1对大鼠缺血心肌VEGF、bFGF的影响。方法:选择雄性Wistar大鼠39只,建立心肌梗死(AMI)模型,术后24h存活大鼠随机分为药物组(n=13)、对照组(n=13),另设假手术组(n=8)。药物组给予三七皂苷R1水溶液(2.5 mg·kg-1·d-1)腹腔注射、对照组及假手术组给予等体积生理盐水腹腔注射,用药4周。于实验终点处死大鼠,心肌组织取材,Ⅷ因子染色计数微血管数(MVC)及微血管密度(MVD),免疫组织化学法观察缺血心肌VEGF、bFGF蛋白的表达。结果:药物组及对照组MVC、MVD均高于假手术组,且药物组高于对照组(P0.05);大鼠缺血心肌药物组及对照组VEGF、bFGF蛋白表达均高于假手术组(P0.05),且药物组高于对照组(P0.05)。结论:三七皂苷R1促进大鼠缺血心肌血管再生同时可上调缺血心肌VEGF、bFGF蛋白水平。     

Inhibition of canonical Wnt signaling promotes gliogenesis in P0-NSCs

Wnt signaling plays an essential role in the development of mammalian central nervous system. We investigated the impact of activation/inhibition of the Wnt signaling pathway on neuronal/glial differentiation in neurospheres derived from neonatal mouse forebrains. For short term alterations, neurospheres were stimulated with recombinant Wnt-3a, Wnt-5a and the Wnt inhibitor Dickkopf-1 (Dkk1). Furthermore, neurospheres were transduced with retroviral vectors encoding Wnt-3a, Wnt-7a and their inhibitors Dkk1 and soluble Frizzled related protein-5 (sFRP5). Long-term activation of Wnt pathway by Wnt-7a or by treatment with GSK3 inhibitors promoted a moderate increase of the neuronal differentiation and blocked gliogenesis. In contrast, Wnt pathway inhibition in neurospheres, induced by retroviral overexpression of either Dkk1 or sFRP5, robustly increased the gliogenesis at the expense of neurogenesis. In summary, our data demonstrate that activation or inhibition of Wnt/β-catenin signaling in neurospheres regulates neuronal and glial differentiation, respectively. Thus, our results suggest that Wnt signaling may also contribute to regulate these processes in the neonatal brain.     

碱性成纤维细胞生长因子(bFGF)在骨组织工程学中的研究进展

碱性成纤维细胞生长因子（bFGF)是近年来研究较为广泛的生长因子之一,对骨组织有着广泛的生物学效应。本文就bFGF的研究进展及其目前在骨组织工程学研究方面的应用做一综述。